11C-labeled KF18446: a potential central nervous system adenosine A2a receptor ligand.

UNLABELLED To develop PET ligands for mapping central nervous system (CNS) adenosine A2a receptors that are localized in the striatum and are coupled with dopamine receptors, 3 11C-labeled xanthine-type adenosine A2a antagonists, [11C]KF18446 ([7-methyl-11C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthin e), [11C]KF19631 ([7-methyl-11C]-(E)-1,3-diallyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanth ine), and [11C]CSC ([7-methyl-11C]-8-chlorostyrylcaffeine), were compared with [11C]KF17837 ([7-methyl-11C]-(E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylx anthine). METHODS The regional brain uptake of the tracers, the effect of the coinjected adenosine antagonists on the uptake, and the metabolism were studied in mice. In rats, the regional brain uptake of the tracers was visualized by ex vivo autoradiography (ARG). The A2a receptor binding of antagonist 1 was also measured by in vitro ARG. Imaging of the monkey brain was performed with PET with antagonist 1. RESULTS In mice, the highest striatal uptake was found for antagonist 1 followed by antagonists 2 and 4. The uptake was inhibited by each of 3 KF compounds and by CSC, but not by an A1 antagonist KF15372. Another selective nonxanthine-type A2a antagonist SCH 58261 significantly decreased the striatal uptake of only antagonist 1, the labeled metabolites of which were less than 20% in the plasma 30 min postinjection, but were negligible in the brain tissue. In ex vivo ARG, antagonist 1 showed the highest striatal uptake and the highest uptake ratio of the striatum to the other brain regions. A high and selective binding of antagonist 1 to the striatum was also confirmed by in vitro ARG. PET with antagonist 1 visualized adenosine A2a receptors in the monkey striatum. CONCLUSION These results indicate that antagonist 1 ([11C]KF18446) is the most suitable PET ligand for mapping adenosine A2a receptors in the CNS.

[1]  M. Kiyosawa,et al.  Evaluation of carbon-11 labeled KF15372 and its ethyl and methyl derivatives as a potential CNS adenosine A1 receptor ligand. , 1997, Nuclear medicine and biology.

[2]  S. Stone-Elander,et al.  In vivo biodistribution of [N-11C-methyl]KF 17837 using 3-D-PET: evaluation as a ligand for the study of adenosine A2A receptors. , 1997, Nuclear medicine and biology.

[3]  S. Synder,et al.  Autoradiographic localization of adenosine receptors in rat brain using [3H]cyclohexyladenosine , 1982, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[4]  E. Ongini,et al.  Binding of the radioligand [3H]‐SCH 58261, a new non‐xanthine A2A adenosine receptor antagonist, to rat striatal membranes , 1996, British journal of pharmacology.

[5]  K. Jacobson,et al.  Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. , 1993, Journal of medicinal chemistry.

[6]  Sergi Ferré,et al.  Adenosine–dopamine receptor–receptor interactions as an integrative mechanism in the basal ganglia , 1997, Trends in Neurosciences.

[7]  J. Palacios,et al.  Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease , 1991, Neuroscience.

[8]  B. Fredholm,et al.  Pharmacology of adenosine A2A receptors. , 1996, Trends in pharmacological sciences.

[9]  M. E. Lewis,et al.  Autoradiographic visualization of rat brain adenosine receptors using N6-cyclohexyl [3H]adenosine. , 1981, European journal of pharmacology.

[10]  J. Fastbom,et al.  The distribution of adenosine a1 receptors and 5'-nucleotidase in the brain of some commonly used experimental animals , 1987, Neuroscience.

[11]  J. Málly,et al.  Potential role of adenosine antagonist therapy in pathological tremor disorders. , 1996, Pharmacology & therapeutics.

[12]  B. Fredholm,et al.  Autoradiographic evidence for G-protein coupled A2-receptors in rat neostriatum using [3H]-CGS 21680 as a ligand , 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

[13]  B B Fredholm,et al.  Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Kubo,et al.  Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure. , 1992, Journal of medicinal chemistry.

[15]  R. Guieu,et al.  Adenosine and the nervous system: clinical implications. , 1996, Clinical neuropharmacology.

[16]  M. Kiyosawa,et al.  Carbon-11-labeled KF15372: a potential central nervous system adenosine A1 receptor ligand. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  B. Parsons,et al.  Neuroleptics Up‐Regulate Adenosine A2a Receptors in Rat Striatum: Implications for the Mechanism and the Treatment of Tardive Dyskinesia , 1995, Journal of neurochemistry.

[18]  B. Fredholm,et al.  The binding of the adenosine A2 receptor selective agonist [3H]CGS 21680 to rat cortex differs from its binding to rat striatum. , 1993, European journal of pharmacology.

[19]  U. Ungerstedt,et al.  Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia , 1994, Neuroscience.